Patients were randomly assigned in a 1:1 ratio with dynamic allocation and minimisation , stratified by biological subtype and Ki-67 level to receive , at the same time as the backbone regimens , either carboplatin ( AUC 15 [ 20 for the first 329 patients ] once a week ) or no carboplatin .